구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Talquetamab |
Overview Company | Janssen |
Overview Modality | ANTIBODY |
Overview Target | FRα |
Overview Indication | Myeloma Multiple; Plasma Cell Leukemia |
Overview Phase | PHASE_3 |
Overview Status | DISCONTINUED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | first-in-class, T-cell-redirecting bispecific antibody targeting GPRC5D, a novel antigen highly expressed on malignant plasma cells wi |
Positioning Known limitation | resistance mechanisms |
MoA Mechanism | , Clinical, and Translational Science |
MoA Biomarker | BCMA (teclistamab) demonstrated unexpectedly high |
PK/PD Species | Cynomolgus monkey, NHP, Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, NHP, Monkey |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Cynomolgus monkey, NHP, Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, NHP, Monkey |
Toxicology Major finding | thrombocytopenia was significantly increased in patients with RI |
Toxicology CRS | Reported |
Clinical Safety signal | thrombocytopenia was significantly increased in patients with RI |
Clinical Program phase | PHASE_3 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Talquetamab |
Overview Company | Janssen |
Overview Modality | ANTIBODY |
Overview Target | FRα |
Overview Indication | Myeloma Multiple; Plasma Cell Leukemia |
Overview Phase | PHASE_3 |
Overview Status | DISCONTINUED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | first-in-class, T-cell-redirecting bispecific antibody targeting GPRC5D, a novel antigen highly expressed on malignant plasma cells wi |
Positioning Known limitation | resistance mechanisms |
MoA Mechanism | , Clinical, and Translational Science |
MoA Biomarker | BCMA (teclistamab) demonstrated unexpectedly high |
PK/PD Species | Cynomolgus monkey, NHP, Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, NHP, Monkey |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Cynomolgus monkey, NHP, Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, NHP, Monkey |
Toxicology Major finding | thrombocytopenia was significantly increased in patients with RI |
Toxicology CRS | Reported |
Clinical Safety signal | thrombocytopenia was significantly increased in patients with RI |
Clinical Program phase | PHASE_3 |
추천 비교
추천 비교